FDA Drug Establishment Registration Versus Drug Listing: Key Differences For Shippers And Manufacturers

FDA Drug Establishment Registration FDA registration for covered establishments engaged in manufacturing, repacking, relabeling, or salvaging drugs for U.S. distribution. Understanding how establishment registration differs from drug listing is critical for manufacturers, labelers, contract packers, and logistics providers that move or process regulated products.

Two related but separate obligations exist: registering the establishment where covered activities occur, and listing the drug products associated with those establishments. Confusing the two is a common operational error; registration identifies the place and legal responsibility, while listing identifies specific products and their formulations, strengths, and labeling.

Primary Distinction

Registration is an obligation tied to a physical facility and the covered activities performed there. Drug listing is tied to each drug product (a formulation and presentation) and must include owner/operator information, container/labeler codes (NDCs where applicable), and the establishments where the product is made, repacked, or labeled.

Why The Difference Matters

• Regulatory Scope: Registration enables FDA to know what sites exist and to schedule inspections or request records; listing enables FDA to track what products are associated with those sites.
• Recall And Traceability: Accurate listing ties product to a manufacturing site, which speeds recalls and root-cause investigations.
• Import Control: For foreign establishments, registration (and proper listing) is a prerequisite for admissibility; incorrect listings can delay or block imports.

Who Typically Submits Each

Generally, the owner or operator of an establishment submits registration for the physical site. The owner or labeler of the drug product submits the product listing to identify items in commercial distribution. In contract manufacturing arrangements, two parties commonly coordinate: the contract facility registers, while the product owner lists the product and identifies the contract facility as a manufacturer or repacker.

Operational Scenarios

• Brand Owner With Contract Manufacturer: The contract maker registers its plant; the brand owner lists the product and includes the contract plant in the product listing.
• Integrator/3PL Holding Inventory Only: A pure storage warehouse that only stores sealed, labeled product and does not perform repacking typically does not register; confirm by reviewing covered operations.
• Relabeling At A 3PL: If a 3PL performs relabeling or repacking, it must register; the product owner must list the product and can identify the 3PL as a repacker.

How The Processes Interact

Registration and listing are completed in related FDA systems and often rely on consistent data (facility names, addresses, FEI numbers). When a regulator needs to trace a product, they use the product listing to find the production or repacking site via the registration record. Therefore, discrepancies between registration and listing entries (different addresses, incorrect activity types) create compliance risk and operational delays.

Practical Steps To Avoid Common Errors

• Coordinate Parties: Establish a standard operating procedure that documents who will register, who will list, and how updates are communicated between brand owner and contract facility.
• Centralize Records: Keep a master register of FEI numbers and product NDCs mapped to physical locations.
• Review Before Import: For imports, verify that foreign establishments are registered and that product listings correctly identify manufacturing and repacking locations before shipment.

In short, the FDA Drug Establishment Registration obligation names and documents the facilities that handle U.S.-bound drug products, while drug listing identifies the products themselves and links them to those facilities; both are required for complete regulatory traceability and compliance.